AU2009317161B2 - High affinity T cell receptor and use thereof - Google Patents
High affinity T cell receptor and use thereof Download PDFInfo
- Publication number
- AU2009317161B2 AU2009317161B2 AU2009317161A AU2009317161A AU2009317161B2 AU 2009317161 B2 AU2009317161 B2 AU 2009317161B2 AU 2009317161 A AU2009317161 A AU 2009317161A AU 2009317161 A AU2009317161 A AU 2009317161A AU 2009317161 B2 AU2009317161 B2 AU 2009317161B2
- Authority
- AU
- Australia
- Prior art keywords
- tcr
- cells
- chain
- cell
- tyrosinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 154
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 152
- 210000004027 cell Anatomy 0.000 claims abstract description 155
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 102
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 46
- 239000000427 antigen Substances 0.000 claims abstract description 36
- 108091007433 antigens Proteins 0.000 claims abstract description 36
- 102000036639 antigens Human genes 0.000 claims abstract description 36
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 31
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 230000003211 malignant effect Effects 0.000 claims abstract description 9
- 102000003425 Tyrosinase Human genes 0.000 claims description 83
- 108060008724 Tyrosinase Proteins 0.000 claims description 83
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 67
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 67
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 49
- 201000001441 melanoma Diseases 0.000 claims description 41
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 29
- 108020004705 Codon Proteins 0.000 claims description 20
- 108020001507 fusion proteins Proteins 0.000 claims description 19
- 102000037865 fusion proteins Human genes 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 238000007792 addition Methods 0.000 claims description 15
- 230000001177 retroviral effect Effects 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 12
- 230000037430 deletion Effects 0.000 claims description 12
- 238000005457 optimization Methods 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 238000011467 adoptive cell therapy Methods 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000037323 Rare tumor Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000013605 shuttle vector Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 87
- 210000004881 tumor cell Anatomy 0.000 description 46
- 210000004698 lymphocyte Anatomy 0.000 description 25
- 101500027794 Thermococcus kodakarensis (strain ATCC BAA-918 / JCM 12380 / KOD1) Homing endonuclease PI-PkoII Proteins 0.000 description 21
- 230000028327 secretion Effects 0.000 description 21
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 239000003446 ligand Substances 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 210000004443 dendritic cell Anatomy 0.000 description 16
- 238000012546 transfer Methods 0.000 description 15
- 230000009089 cytolysis Effects 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 238000003501 co-culture Methods 0.000 description 11
- 206010022000 influenza Diseases 0.000 description 11
- 208000006265 Renal cell carcinoma Diseases 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 230000000735 allogeneic effect Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102000008070 Interferon-gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 229960003130 interferon gamma Drugs 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 7
- 102000004503 Perforin Human genes 0.000 description 7
- 108010056995 Perforin Proteins 0.000 description 7
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229930192851 perforin Natural products 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000011476 stem cell transplantation Methods 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000037452 priming Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- 102000011786 HLA-A Antigens Human genes 0.000 description 4
- 108010075704 HLA-A Antigens Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 101000611536 Agaricus bisporus Polyphenol oxidase 3 Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 101000611541 Sarcophaga argyrostoma Phenoloxidase 3 Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003239 susceptibility assay Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
- 108010059234 HLA-DPw4 antigen Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000772138 Homo sapiens T cell receptor alpha variable 1-2 Proteins 0.000 description 1
- 101000658388 Homo sapiens T cell receptor beta variable 13 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710150912 Myc protein Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 102100029308 T cell receptor alpha variable 1-2 Human genes 0.000 description 1
- 102100034886 T cell receptor beta variable 13 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101150002618 TCRP gene Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010021994 cytomegalovirus matrix protein 65kDa Proteins 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08020396 | 2008-11-24 | ||
| EP08020396.1 | 2008-11-24 | ||
| PCT/EP2009/065705 WO2010058023A1 (en) | 2008-11-24 | 2009-11-24 | High affinity t cell receptor and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009317161A1 AU2009317161A1 (en) | 2010-05-27 |
| AU2009317161B2 true AU2009317161B2 (en) | 2014-09-11 |
Family
ID=40521958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009317161A Active AU2009317161B2 (en) | 2008-11-24 | 2009-11-24 | High affinity T cell receptor and use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US8697854B2 (enExample) |
| EP (1) | EP2352756B1 (enExample) |
| JP (2) | JP6069755B2 (enExample) |
| CN (1) | CN102272153B (enExample) |
| AU (1) | AU2009317161B2 (enExample) |
| CA (1) | CA2743669C (enExample) |
| DK (1) | DK2352756T3 (enExample) |
| ES (1) | ES2394180T3 (enExample) |
| WO (1) | WO2010058023A1 (enExample) |
Families Citing this family (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10112851C1 (de) | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| IL296832A (en) | 2005-10-18 | 2022-11-01 | Nat Jewish Health | Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin |
| IL287311B2 (en) | 2008-05-16 | 2024-06-01 | Taiga Biotechnologies Inc | Antibodies and processes for their preparation |
| EP2318435B1 (en) | 2008-08-28 | 2015-12-23 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
| AU2009317161B2 (en) * | 2008-11-24 | 2014-09-11 | Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
| WO2010089412A1 (en) * | 2009-02-09 | 2010-08-12 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US12492376B2 (en) | 2009-10-29 | 2025-12-09 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| US9891211B2 (en) | 2012-03-28 | 2018-02-13 | Gadeta B.V. | Gamma 9 delta 2 T cell receptors |
| RU2018130123A (ru) | 2012-05-03 | 2018-11-07 | Фред Хатчинсон Кансэр Рисёч Сентер | Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии |
| US9790278B2 (en) | 2012-05-07 | 2017-10-17 | The Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
| WO2014015312A1 (en) | 2012-07-20 | 2014-01-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| GB201309421D0 (en) * | 2013-05-24 | 2013-07-10 | Imp Innovations Ltd | Polypeptides |
| WO2014206304A1 (zh) * | 2013-06-26 | 2014-12-31 | 广州市香雪制药股份有限公司 | 高稳定性的t细胞受体及其制法和应用 |
| WO2015077615A1 (en) * | 2013-11-22 | 2015-05-28 | The Board Of Trustees Of The University Of Illinois | Engineered high-affinity human t cell receptors |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| WO2015113140A1 (en) * | 2014-01-29 | 2015-08-06 | University Health Network | Methods and compositions for producing a cell expressing a t cell receptor |
| CA2939305A1 (en) | 2014-02-27 | 2015-09-03 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| EP3177314B1 (en) | 2014-08-04 | 2020-10-07 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| EP3212774A4 (en) * | 2014-10-31 | 2018-04-11 | Baylor College of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| CA2966300C (en) * | 2014-11-03 | 2023-07-11 | Mirjam H.M. Heemskerk | T cell receptors directed against bob1 and uses thereof |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| WO2016187508A2 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
| EP3298131B1 (en) | 2015-05-20 | 2023-04-26 | The Regents of The University of California | Method for generating human dendritic cells for immunotherapy |
| AU2016267155A1 (en) * | 2015-05-26 | 2017-12-21 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
| CA2987289A1 (en) | 2015-06-11 | 2016-12-15 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
| WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| KR20180048743A (ko) * | 2015-09-04 | 2018-05-10 | 토카겐 인크. | 2a 펩타이드를 포함하는 재조합 벡터 |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
| AU2016343682A1 (en) * | 2015-10-30 | 2018-06-14 | The Regents Of The University Of California | Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells |
| US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
| WO2017139405A1 (en) * | 2016-02-08 | 2017-08-17 | The General Hospital Corporation | Method of reducing tolerization of t cells to tumor antigens |
| SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| KR102397674B1 (ko) | 2016-04-01 | 2022-05-18 | 카이트 파마 인코포레이티드 | Bcma 결합 분자 및 그의 사용 방법 |
| UA128781C2 (uk) | 2016-04-01 | 2024-10-23 | Кайт Фарма, Інк. | Т-клітина, спосіб її отримання та застосування |
| EP3443123B1 (en) * | 2016-04-11 | 2021-08-11 | Board of Regents, The University of Texas System | Methods and compositions for detecting single t cell receptor affinity and sequence |
| WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
| WO2017212074A1 (en) | 2016-06-10 | 2017-12-14 | Umc Utrecht Holding B.V. | Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response |
| WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| WO2018064208A1 (en) | 2016-09-28 | 2018-04-05 | The Broad Institute, Inc. | Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| US12227578B2 (en) | 2016-11-11 | 2025-02-18 | The Broad Institute, Inc. | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action |
| CN110177758B (zh) | 2016-12-02 | 2021-10-01 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
| MD3551221T2 (ro) * | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| US11752172B2 (en) | 2017-01-04 | 2023-09-12 | Nova Southeastern University | Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| EP3580561B1 (en) | 2017-02-12 | 2023-11-01 | BioNTech US Inc. | Hla-based methods and compositions and uses thereof |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| MX2019012398A (es) | 2017-04-18 | 2020-09-25 | Broad Inst Inc | Composiciones para detectar secreciones y metodos de uso. |
| WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| EP3625342B1 (en) | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| WO2018211115A1 (en) | 2017-05-18 | 2018-11-22 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| US11572541B2 (en) | 2017-06-09 | 2023-02-07 | Providence Health & Services—Oregon | Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer |
| US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| JP6731114B2 (ja) | 2017-08-03 | 2020-07-29 | タイガ バイオテクノロジーズ，インク． | メラノーマの処置のための方法および組成物 |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| AU2018328220C1 (en) * | 2017-09-05 | 2026-01-08 | Seattle Project Corp. | Neoantigen identification for T-cell therapy |
| WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| US20200308279A1 (en) | 2017-10-06 | 2020-10-01 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
| WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| EP3773633A4 (en) | 2018-04-06 | 2022-01-26 | The Regents of The University of California | METHODS OF TREATMENT OF GLIOBLASTOMA |
| EP3773632A4 (en) | 2018-04-06 | 2022-05-18 | The Regents of The University of California | Methods of treating egfrviii expressing glioblastomas |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
| US12460244B2 (en) | 2018-08-20 | 2025-11-04 | The Broad Institute, Inc. | Inhibitors of RNA-guided nuclease activity and uses thereof |
| WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| WO2020132087A1 (en) * | 2018-12-18 | 2020-06-25 | Mbl International Corp. | COMPOSITIONS OF STREPTAVIDIN-OLIGO CONJUGATES OF VARYING pMHC OCCUPANCY |
| MX2021007556A (es) | 2018-12-21 | 2021-09-10 | Biontech Us Inc | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| BR112021016875A2 (pt) | 2019-03-01 | 2022-01-04 | Iovance Biotherapeutics Inc | Processo para expansão de linfócitos de sangue periférico |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| JP2022527117A (ja) | 2019-04-08 | 2022-05-30 | タイガ バイオテクノロジーズ，インク． | 免疫細胞の凍結保存のための組成物および方法 |
| EP3969041A4 (en) | 2019-05-14 | 2023-05-10 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| CN110357953B (zh) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | 识别人巨细胞病毒pp65抗原的TCR |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US12195723B2 (en) | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| CA3172895A1 (en) * | 2020-02-27 | 2021-09-02 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
| EP4121101A1 (en) * | 2020-03-16 | 2023-01-25 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific t cell receptors and t cell epitopes |
| JP7518915B2 (ja) | 2020-04-01 | 2024-07-18 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｃｄ３融合タンパク質およびその使用 |
| WO2021236548A1 (en) * | 2020-05-18 | 2021-11-25 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
| US20240150711A1 (en) | 2021-03-01 | 2024-05-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
| AU2022288058A1 (en) | 2021-06-07 | 2023-11-16 | Agonox, Inc. | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| CN113929767B (zh) * | 2021-10-14 | 2023-11-24 | 深圳大学总医院 | 具有高亲和力的t细胞受体及其用途 |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
| WO2024226838A2 (en) | 2023-04-25 | 2024-10-31 | The Brigham And Women's Hospital, Inc. | Treatment of autoimmune diseases having a pathogenic t cell state |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415553A (en) | 1973-08-06 | 1983-11-15 | Dso "Pharmachim" | Compositions, processes for their preparation and method for treatment of neoplasms |
| US4568542A (en) | 1981-06-09 | 1986-02-04 | Lee Biomolecular Research Laboratories, Inc. | Vaccine compositions |
| JPH0751511B2 (ja) | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン２を含有してなる癌治療剤 |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US5582831A (en) | 1991-11-26 | 1996-12-10 | Yeda Research And Development Co., Ltd. | Anti-tumor vaccines |
| US5156841A (en) | 1988-08-26 | 1992-10-20 | United States Of America | Anti-tumor vaccine |
| US5290551A (en) | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
| US6077519A (en) | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
| DE69534880T2 (de) | 1994-07-29 | 2007-02-22 | Sunol Molecular Corp., Miramar | Mhc-komplexe und verwendungen davon |
| EP0831860B1 (en) | 1995-05-25 | 2004-10-20 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| WO1997032603A1 (en) * | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6458585B1 (en) | 1996-08-14 | 2002-10-01 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
| US6063375A (en) | 1996-09-10 | 2000-05-16 | Medical University Of South Carolina | Semiallogeneic cell hybrids and related methods for treating cancer |
| CA2278678A1 (en) | 1997-01-31 | 1998-08-06 | Research Corporation Technologies, Inc. | Cancer immunotherapy with semi-allogeneic cells |
| WO1998058956A2 (en) | 1997-06-23 | 1998-12-30 | Ludwig Institute For Cancer Research | Methods for inducing an immune response involving prime-boost protocols |
| CA2296366A1 (en) | 1997-07-21 | 1999-01-28 | Cerus Corporation | Method of treating leukocytes, leukocyte compositions and methods of use thereof |
| WO2000076537A2 (en) | 1997-09-10 | 2000-12-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases |
| AU1601801A (en) | 1999-11-16 | 2001-05-30 | Eric M. Eastman | Methods of preparing crna |
| US20020123479A1 (en) | 1999-12-08 | 2002-09-05 | Song Elizabeth S. | Immunostimulation mediated by gene-modified dendritic cells |
| AU2599002A (en) | 2000-10-20 | 2002-04-29 | Tsuneya Ohno | Fusion cells and cytokine compositions for treatment of disease |
| EP1201760A1 (en) | 2000-10-30 | 2002-05-02 | ARTEMIS Pharmaceuticals GmbH | Influenza virus vector for human dendritic cells |
| US20040260061A1 (en) | 2001-03-12 | 2004-12-23 | Keld Kaltoft | Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity |
| DE10112851C1 (de) | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
| DE10132502A1 (de) | 2001-07-05 | 2003-01-23 | Gsf Forschungszentrum Umwelt | Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen |
| EP1420253B1 (de) | 2002-08-23 | 2006-05-31 | Deutsches Rheuma-Forschungszentrum Berlin | Verfahren zum Nachweis und zur Isolierung von T-Lymphozyten, die ein definiertes Antigen erkennen |
| CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| DK1814580T3 (en) | 2004-11-24 | 2016-12-12 | Hutchinson Fred Cancer Res | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| ES2672895T3 (es) * | 2005-08-05 | 2018-06-18 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | Generación de células T específicas de antígeno |
| EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| PT2016102E (pt) | 2006-05-03 | 2012-05-15 | Us Gov Health & Human Serv | Recetores de célula t quimérica e materiais relacionados e métodos de uso |
| EP1870418A1 (en) | 2006-06-20 | 2007-12-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Allorestricted peptide-specific T cells |
| EP1878744A1 (en) | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| EP1932537A1 (en) | 2006-12-12 | 2008-06-18 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Expression of transgenic T cell receptors in LAK-T cells |
| JP5292550B2 (ja) * | 2007-03-23 | 2013-09-18 | 静岡県 | Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子 |
| EP2514766A3 (en) * | 2007-03-29 | 2013-06-05 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| US20110280894A1 (en) | 2008-07-31 | 2011-11-17 | Angela Krackhardt | Her2/neu specific t cell receptors |
| AU2009317161B2 (en) * | 2008-11-24 | 2014-09-11 | Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
| WO2010089412A1 (en) * | 2009-02-09 | 2010-08-12 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| EP3212774A4 (en) * | 2014-10-31 | 2018-04-11 | Baylor College of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| WO2016178167A1 (en) * | 2015-05-04 | 2016-11-10 | Vcn Biosciences Sl | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
| JP7518915B2 (ja) * | 2020-04-01 | 2024-07-18 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｃｄ３融合タンパク質およびその使用 |
-
2009
- 2009-11-24 AU AU2009317161A patent/AU2009317161B2/en active Active
- 2009-11-24 DK DK09760145.4T patent/DK2352756T3/da active
- 2009-11-24 JP JP2011536895A patent/JP6069755B2/ja active Active
- 2009-11-24 ES ES09760145T patent/ES2394180T3/es active Active
- 2009-11-24 WO PCT/EP2009/065705 patent/WO2010058023A1/en not_active Ceased
- 2009-11-24 EP EP09760145A patent/EP2352756B1/en active Active
- 2009-11-24 CA CA2743669A patent/CA2743669C/en active Active
- 2009-11-24 US US13/130,665 patent/US8697854B2/en active Active
- 2009-11-24 CN CN200980154272.4A patent/CN102272153B/zh active Active
-
2014
- 2014-03-25 US US14/224,525 patent/US9862755B2/en active Active
-
2015
- 2015-06-23 JP JP2015125543A patent/JP2015211682A/ja not_active Withdrawn
-
2017
- 2017-11-27 US US15/822,970 patent/US10626159B2/en active Active
-
2020
- 2020-03-17 US US16/820,856 patent/US20200339653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015211682A (ja) | 2015-11-26 |
| US20140348805A1 (en) | 2014-11-27 |
| CA2743669C (en) | 2018-10-16 |
| US20200339653A1 (en) | 2020-10-29 |
| AU2009317161A1 (en) | 2010-05-27 |
| JP6069755B2 (ja) | 2017-02-01 |
| US8697854B2 (en) | 2014-04-15 |
| JP2012509659A (ja) | 2012-04-26 |
| CA2743669A1 (en) | 2010-05-27 |
| US20110280889A1 (en) | 2011-11-17 |
| CN102272153B (zh) | 2015-04-15 |
| ES2394180T3 (es) | 2013-01-23 |
| DK2352756T3 (da) | 2012-12-03 |
| US20180162921A1 (en) | 2018-06-14 |
| WO2010058023A1 (en) | 2010-05-27 |
| US9862755B2 (en) | 2018-01-09 |
| EP2352756A1 (en) | 2011-08-10 |
| CN102272153A (zh) | 2011-12-07 |
| US10626159B2 (en) | 2020-04-21 |
| EP2352756B1 (en) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10626159B2 (en) | High affinity T cell receptor and use thereof | |
| AU2015230741B2 (en) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof | |
| EP2041171B1 (en) | Epitope-tag for surface-expressed proteins and uses thereof | |
| JP2022133308A (ja) | キメラアロ抗原受容体ｔ細胞の組成物および方法 | |
| EP3099708B1 (en) | Methods and compositions for producing a cell expressing a t cell receptor | |
| KR20190016507A (ko) | TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체 | |
| US20230399402A1 (en) | Hla class ii-restricted tcrs against the kras g12>v activating mutation | |
| US20200308279A1 (en) | Chimeric antigen receptors | |
| JP2021519107A (ja) | 膜結合型ＩＬ−１０を発現する遺伝子的にリプログラミングされたＴｒｅｇ | |
| JP2021532814A (ja) | Ｈａ−１特異的ｔ細胞受容体およびその使用 | |
| Schaft et al. | An altered gp100 peptide ligand with decreased binding by TCR and CD8α dissects T cell cytotoxicity from production of cytokines and activation of NFAT | |
| GB2569692A (en) | T cell antigen receptor chimera |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |